Kura Oncology (KURA) Current Assets (2010 - 2026)

Kura Oncology (KURA) has 17 years of Current Assets data on file, last reported at $623.8 million in Q1 2026.

• Current Assets for Q1 2026 came in at $623.8 million, down 13.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $623.8 million (down 13.87% YoY), and the FY2025 annual result was $708.7 million, down 4.86% from the prior year.
• Current Assets fell to $623.8 million in Q1 2026 per KURA's latest filing, from $708.7 million in the prior quarter.
• Over five years, Current Assets peaked at $744.8 million in Q4 2024 and troughed at $416.4 million in Q1 2023.
• A 5-year average of $541.6 million and a median of $487.0 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets retreated 20.5% in 2022, then surged 72.22% in 2024.
• A 5-year view of Current Assets shows it stood at $446.4 million in 2022, then slipped by 3.12% to $432.5 million in 2023, then soared by 72.22% to $744.8 million in 2024, then retreated by 4.86% to $708.7 million in 2025, then declined by 11.98% to $623.8 million in 2026.
• Business Quant data shows KURA's Current Assets at $623.8 million in Q1 2026, $708.7 million in Q4 2025, and $620.7 million in Q3 2025.